Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
Abstract Background The treatment of tuberous sclerosis complex (TSC) using mammalian target of rapamycin (mTOR) inhibitors is clinically promising. The aim of the present study was to evaluate the efficacy and safety of mTOR inhibitors for improving the clinical symptoms of TSC. Methods We performe...
Main Authors: | Min Li, Ying Zhou, Chaoyang Chen, Ting Yang, Shuang Zhou, Shuqing Chen, Ye Wu, Yimin Cui |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-02-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13023-019-1012-x |
Similar Items
-
Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
by: Won Seop Kim
Published: (2011-06-01) -
mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model
by: Alice Polchi, et al.
Published: (2018-05-01) -
Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
by: Cabrera-López Cristina, et al.
Published: (2012-11-01) -
Treatment of Cardiac Rhabdomyomas with mTOR Inhibitors in Children with Tuberous Sclerosis Complex—A Systematic Review
by: Monika Sugalska, et al.
Published: (2021-05-01) -
Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age – a multicenter retrospective study
by: Afshin Saffari, et al.
Published: (2019-05-01)